|
|
 |
|
Viewing report
|
|
|
|
U.S. Research Biochemicals Markets
Frost & Sullivan, Feb 2002
Expansion of Sequence Data Drives Reagent Usage
The increasing availability of gene sequencing information through public and
commercial initiatives is facilitating easier application of technologies that
require sequential understanding, such as proteomics and functional genomics.
As a result, demand is rising for a range of research biochemicals, the reactive
agents that researchers use in those fields. The need for enzymes, monomeric
compound subunits, antibodies, and purification matrices will grow steadily
over the forecast period.
This Frost & Sullivan study analyzes the markets for essential research
biochemicals, including molecular biology reagents, DNA research
consumables, immunochemistry reagents, and cell culture reagents. For each
segment, the study examines technology trends, evaluates products, and tracks
the competition, providing an in-depth perspective on some of the most
promising areas of life sciences.
Loss of Patent Protection Transforms Some Products into Commodities
Research biochemical markets must moderate the influence of decreasing
patent protections, or risk being dominated by commodity dynamics, says the
author of this study. Older products in this marketplace, such as restriction
enzymes, have lost patent protection worldwide. As more companies have
access to these technologies, competition will intensify and prices will drop.
The question is how to maintain or increase profit margins when setting a
higher price means quickly losing customers to the competition, states the
analyst. For some companies, the solution may be to use products no longer
protected by patents in the development of combination products. This study,
which highlights emerging challenges and discusses potential solutions, can
help your company anticipate and overcome hurdles that lay ahead.
Strong Brand Image Defines Market Leaders
Market leaders in the research biochemicals industry have well-respected,
long-standing brand names, says the author. In addition, successful firms have
efficient distribution networks, broad product lines, and a web of licensing and
partnership relationships.
All of these factors combine to make market entry almost impossible for
a new company, and the expansion of an existing participant’s market share
nearly as difficult. By surveying the competitive landscape and
pinpointing winning strategies, this study is a valuable tool for overtaking
uninformed competitors.
Additional Information
Market Participants
Abgenix, Inc.
Alexis Biochemicals Corp.
Ambion, Inc.
Amersham Biosciences
Applied Biosystems Group
Beckman Coulter, Inc.
BD Biosciences - Pharmingen
BioNexus, Inc.
Bio-Rad Laboratories, Inc.
BioWhittaker, Inc.
Boehringer Mannheim Corp.
Boston Probes, Inc.
Brinkmann Instruments, Inc.
Epicentre Technologies
Fermentas, Inc.
Finnzymes
Fisher Scientific International, Inc.
Gemini Biotech
Genisphere, Inc.
GenHunter Corp.
Geno Technology, Inc.
Genoquest, Inc.
Genpak, Inc.
Glen Research Corp.
Green Mountain Antibodies, Inc.
Hukabel Scientific Ltd.
Hyclone Laboratories, Inc.
ICN Biomedicals, Inc.
IGEN International, Inc.
Idaho Technology, Inc.
Invitrogen Corp.
JRH Biosciences, Inc.
MBI Fermentas, Inc.
Merck Ltd. & CN Biosciences - CALBIOCHEM
Molecular Biosciences, Inc.
Monomer Sciences, Inc.
New England Biolabs, Inc.
Novagen, Inc.
NuGEN Technologies, Inc.
Orchid Biosciences, Inc.
Oxford Biomedical Research
PanVera Corp.
PerkinElmer Life Sciences
Promega Corp.
QIAGEN Genomics
Quality Controlled Biochemicals
Roche Applied Science
Sigma-Aldrich Corp.
Stratagene
United States Biological
Zymed Laboratories, Inc.
|
|
|
|
